Skip to content
‹ Back to IndustriesHealthcare

The University of Kansas Announces Grant Funding for Knee Imaging Biomarkers Acquired from Weight Bearing CT

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT imaging and the critical need for more sensitive and affordable imaging biomarkers.

Osteoarthritis (OA) is the most prevalent form of arthritis, and the knee is the most commonly affected weight-bearing joint. The high cost of clinical trials creates a barrier for effective treatment development. Therefore, introduction of more specific and sensitive biomarkers could help to advance therapeutic development by reducing the time and sample sizes required for clinical trials.

Proposed Outcomes

There is an urgent need for imaging biomarkers that allow for identification of the best time in which patients will respond to treatment, and a means to analyze the efficiency of interventions. Early studies demonstrated the diagnostic value of bilateral weight-bearing CT in identifying knee OA symptoms accurately, as well as the feasibility to detect meniscal tears not detected by non-weight bearing MRI.

The grant from NIAMS will fund a study to validate the proposed imaging biomarkers and begin the qualification process for more responsive OA imaging biomarkers acquired using low-dose, bilateral standing CT imaging. Substantial advantages are offered over traditional radiographic biomarkers, including increased responsiveness to temporal changes in the joints, and a better reflection of the symptoms and severity of the disease. Additionally, this research will determine the prognostic validity of standing CT findings for detecting progression and worsening pain in people who currently suffer from or are at risk for knee OA.

Long-Term Impact

With the support of NIAMS, this research holds promise to detect joint damage earlier, and accelerate the pace of scientific discovery and clinical trials. The continuing impact will be evident through a shift in knee joint imaging with an improved biomarkers for monitoring knee OA disease features. If the additional meniscal extrusions detected on bilateral standing CT are clinically relevant, then standing CT could improve identification of the most appropriate patients for clinical trials – those at risk of rapid OA progression. Successful completion will provide improved biomarkers that will help those who suffer from knee OA through making clinical trials more affordable and accelerating therapeutic improvement.

For more information on visualizing cartilage and menisci in the knee using standing CT arthrogram versus MRI, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

SCI recruits funeral sales as the career AI cannot replace

SCI recruits funeral sales as the career AI cannot replace

SCI's recruiting video positions funeral and cremation sales as a career resistant to automation by emphasizing the human trust required in end-of-life planning. The pitch frames the role as requiring both compassion and sales drive, targets people outside the industry, and leans on demographic demand from an aging population to argue for job stability.

  • 01More than 11,000 Americans turn 65 daily, SCI says demand will grow.
  • 02SCI seeks candidates with dual traits: compassion and empathy alongside sales-oriented drive and tenacity.
  • 03The role requires no prior industry experience; SCI provides training, coaching, and technology to prepare newcomers.

Oct 7, 2026

CURORI Details Readiness Framework for Planned Ten-City Expansion in China

CURORI, a China-based medical-aesthetic coordination platform founded in 2025, has outlined a readiness framework to expand its city coverage from five to ten Chinese destinations by the end of 2027. The expansion will be phased around provider and service readiness rather than destination count alone, with review areas including qualified doctors, licensed institutions, procedure categories, communication processes, and practical factors for international users.

  • 01CURORI plans to expand from five currently served cities (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou) to ten by December 31, 2027, with Chengdu, Xi'an, Wuhan, and two additional locations under evaluation.
  • 02The company's readiness framework requires operational checks across provider qualifications, licensed institutions, procedure availability, assessment requirements, communication processes, quotation clarity, appointment coordination, and follow-up arrangements before launching in new cities.
  • 03CURORI has a separate objective to help reduce client costs by approximately 10% by the end of 2026 through comparison, clearer quotation information, free initial coordination, and future incentives.

Oct 7, 2026

Some hospices saw daily patient census rise 50% in the 18 to 36 months after rebranding

Some hospices saw daily patient census rise 50% in the 18 to 36 months after rebranding

Some hospice clients saw ADC climb 50% in 18 to 36 months. Expanding beyond hospice is the biggest driver, and the payoff takes years.

  • 01Service diversification beyond hospice care is one of three common rebrand triggers, so the name often trails a business that has already changed.

Oct 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512